CheckMate-9LA

一行要約

1L 進行 NSCLC への Nivo+Ipi + 限定 2 cycles platinum-doublet vs 4 cycles platinum-doublet の phase III。Dual IO の長期効果 + 限定化療の早期 disease control という hybrid strategy で OS HR 0.66。CheckMate-227 dual IO + KEYNOTE-189 IO+chemo paradigm を融合。

試験デザイン

• 対象: Stage IV NSCLC、未治療、EGFR/ALK 陰性、N=719 (1:1)
• 介入群 (n=361) : Nivolumab 360mg q3w + Ipilimumab 1mg/kg q6w + 2 cycles 限定 platinum-doublet (cisplatin or carbo + pemetrexed/paclitaxel) → Nivo+Ipi maintenance
• 対照群 (n=358) : 4 cycles platinum-doublet → optional pemetrexed maintenance (非扁平のみ)

主要結果

• OS (primary) : HR 0.66 (95% CI 0.55–0.80, p<0.0001), median 14.1 vs 10.7 mo
• PFS: HR 0.68, median 6.7 vs 5.0 mo
• ORR: 38% vs 25%
• 4-year OS update (Reck JTO 2024) : 21% vs 11%, plateau formation
• AE: Grade 3-4 47% vs 38% (dual IO + 化療で増加)

臨床的意義

• Dual IO + 限定 chemo の hybrid strategy を 1L 標準選択肢化
• 限定 chemo (2 cycles) で早期 disease control 確保 + dual IO で long-term plateau
• CheckMate-227 chemo-free dual IO の rapid progressor (liver met / 高 disease burden) 対策
• KEYNOTE-189 IO+chemo (4 cycles 化療) と異なる化療 burden の選択肢

Open Questions

• CheckMate-9LA vs KEYNOTE-189 selection: 2 cycles 限定 chemo + dual IO の優位性は？
• PD-L1 全カテゴリで benefit: <1%, 1–49%, ≥50% subset 分析
• Long-term plateau の cure fraction: 5+ yr 以降の survival curve
• AE 増加とのバランス: CRS-like / multi-organ irAE の管理

重要論文 Top 10

1. ★★★★★ Paz-Ares et al. LancetOncol 2021 — CheckMate-9LA primary publication
2. JTO-2024-Reck-First-line nivolumab plus ipilimumab plus chemotherapy in patients with advanced non-small cell lung cancer CheckMate 9LA 4-year follow-up — 4-yr update — long-term plateau
3. CheckMate-227 — chemo-free dual IO comparator — NEJM 2019
4. ★★★★ Gandhi et al. NEnglJMed 2018 — KEYNOTE-189 — IO+chemo (4 cycles)
5. ★★★★ Paz-Ares et al. NEnglJMed 2018 — KEYNOTE-407 — squamous IO+chemo

関連エンティティ

• 薬剤クラス: PD-1-inhibitor / CTLA-4-inhibitor / Platinum-chemotherapy / Pemetrexed
• 関連試験: CheckMate-227 / KEYNOTE-189 / CheckMate-816
• ドメイン: lung-cancer-treatment

関連論文

Basic-Others

• Wolchok et al. NEnglJMed 2013 — Nivolumab plus ipilimumab in advanced melanoma
• Wolchok et al. NEnglJMed 2017 — Overall survival with combined nivolumab and ipilimumab in advanced melanoma

Clinical-Epidemiology

• Ganti et al. JAMAOncol 2021 — Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US

Clinical-NSCLC-Driver negative

• Kanda et al. AnnOncol 2016 — Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell
• Borghaei et al. ClinCancerRes 2026 — Early detriment analysis of first-line nivolumab plus ipilimumab-based therapy in patients with metastatic non-small
• Galetta et al. ClinLungCancer 2011 — Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus
• Peruzzo et al. ClinLungCancer 2025 — Chemotherapy plus anti-PD-1 or anti-PD-L1 in advanced PD-L1-negative squamous cell lung carcinoma A systematic review
• Reck et al. ESMOOpen 2021 — First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in
• Gridelli et al. ESMOOpen 2022 — First-line immunotherapy in advanced NSCLC patients with ECOG PS 2 results of an international expert Panel meeting b…
• Carbone et al. ESMOOpen 2025 — Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung
• Li et al. FrontImmunol 2026 — The application and challenges of immune checkpoint inhibitors in lung cancer therapy
• DiFederico et al. JAMAOncol 2026 — PD-(l)1 inhibitor monotherapy vs chemoimmunotherapy
• Peters et al. JThoracOncol 2025 — Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic nsclc five-year
• Hellmann et al. LancetOncol 2017 — Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012) results of an
• Garassino et al. LancetOncol 2020 — Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously
• Goldberg et al. LancetOncol 2020 — Pembrolizumab for management of patients with NSCLC and brain metastases long-term results and biomarker analysis from
• Paz-Ares et al. LancetOncol 2021 — First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung
• DiFederico et al. LancetOncol 2025 — Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in
• Kaira et al. Medicina(Kaunas) 2021 — Clinical effectiveness of immune checkpoint inhibitors in non-small-cell lung cancer with a poor performance status
• Hellmann et al. NEnglJMed 2018 — Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
• Wang et al. NatMed 2021 — Toward personalized treatment approaches for non-small-cell lung cancer